Endoxan®

DRUG3 trials

Sponsors

NSABP Foundation Inc., Pfizer Inc., I.F.O. Istituti Fisioterapici Ospitalieri

Conditions

Patients with early breast cancermetastatic urothelial cancerrecurrent or refractory neuroblastomarecurrent/refractory Ewing sarcoma

Phase 1

A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

CompletedCTIS2024-511975-14-00

Pfizer Inc.recurrent or refractory neuroblastoma, recurrent/refractory Ewing sarcoma

Start: 2022-05-26End: 2025-08-06Target: 29Updated: 2025-09-08

Phase 2

PembrolizuMab beyond RECIST progression and oral metroNOmic cyclophosphamide in meTAstatic UROthelial cancer: a single-arm, monocentre, phase 2 trial: minotaURO study

CompletedCTIS2024-514979-17-04

I.F.O. Istituti Fisioterapici Ospitalierimetastatic urothelial cancer

End: 2025-10-08Target: 43Updated: 2025-02-24

Phase 3

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo "GeparDouze"

CompletedCTIS2023-508472-11-00

NSABP Foundation Inc.Patients with early breast cancer

Start: 2018-06-13End: 2025-11-19Target: 978Updated: 2025-08-05